HFPEF-project: Heart Failure Phenotyping - Exploring the Fingerprints

Heart Failure With Preserved Ejection Fraction Clinical Trial

— HFpEF-project  

Official title:

HFPEF-project: Heart Failure Phenotyping - Exploring the Fingerprints. Prospective Observational Study Aiming at Detailed Characterization and Deep Phenotyping of Patients With Heart Failure and Preserved Ejection Fraction (LVEF>40%)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06465043
• Other study ID #: HUS/628/2024
• Status: Not yet recruiting
• Start date: June 2024
• Est. completion date: June 2030

Study information

• Verified date: June 2024
• Source: University of Helsinki
• Contact: Johan Lassus, Md.; Ph.D
• Phone: +358 50 4284708
• Email: johan.lassus[@]hus.fi
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

With an ageing population, the number of patients with heart failure with preserved ejection fraction (HFpEF) or diastolic heart failure is increasing rapidly. This condition is associated with significantly increased morbidity and mortality, but effective treatment options that improve prognosis are very limited. Further understanding of the nature and determinants of this disease is needed to develop better treatments of HFpEF and to improve the prognosis and quality of life of these patients. This study will collect a comprehensive, prospective dataset of patients with HFpEF and determine which factors influence the prognosis of this patient group. The specific aim is to create an accurate description of the spectrum and subtypes of HFpEF enabling better tools to plan and implement individualised treatment for patients. The main objectives of the study are: - to describe and categorize the phenotype of HFpEF patients (deep phenotyping) using the latest biochemical, functional and imaging techniques - identifying factors affecting prognosis and potential new prognostic markers - prospective follow-up of a contemproary cohort of HFpEF patients to assess outcomes, such as hospitalisations for heart failure, mortality, and quality of life - identification of specific or aberrant HFpEF phenotypes for genetic studies. Target population: - Patients (minimum18 years old) with hospitalization for heart failure (1' or 2' cause for hospitalization) or outpatients with heart failure AND - Left ventricular ejection fraction (LVEF) >40% within 12 months prior to or during index hospitalization (assessed by ECHO, MRI, LV-cineangiography or radionuclide imaging) AND - Elevated BNP/NTproBNP AND - Impaired myocardial relaxation (diastolic dysfunction) assessed by tissue doppler imaging (TDI) velocities on ECHO: lateral mitral annulus velocity (lat E') >9cm/s or septal annulus velocity (sept E') >8 cm/s - Both de-novo HF and patients with previously diagnosed HF will be eligible The study prospective, observational study is carried out at Helsinki and Uusimaa Hospital District (HUS).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 300
• Est. completion date: June 2030
• Est. primary completion date: December 2029
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Hospitalisation for heart failure or debilitating dyspnoea (NYHA II-IV) and a diagnosis of HFpEF.
• Left ventricular ejection fraction (LVEF) >40% in the preceding 12 months or during a period of hospitalisation as determined by either cardiac ultrasound, MRI, left ventricular echocardiography, or isotope imaging.
• NTproBNP > 300 pg/ml (or BNP > 100 pg/ml) during hospitalisation or NTproBNP > 125 pg/ml in outpatients.
• Impaired myocardial relaxation (diastolic dysfunction) as determined by tissue doppler imaging (TDI: lateral mitral annulus velocity, lat E' <9cm/s or septal annulus velocity, sept E' <8 cm/s)
• Both previously undiagnosed, de-novo heart failure patients and patients admitted to hospital for acute exacerbation of known heart failure will be included in the study.

Exclusion Criteria:

• Age >85 years
• Significant aortic valve stenosis (AVA =1.0 cm2)
• Primary (structural) mitral valve disease with grade III-IV insufficiency or significant stenosis (MVA<1.5 cm2)
• Other severe valvular defect (e.g. secondary severe mitral or severe tricuspid insufficiency)
• Previous LVEF < 40% (HFrEF or HF with improved EF)
• Recent acute coronary syndrome (< 3 months) or myocardial infarction with ST elevations (STEMI) within 12 months
• Previous open heart surgery (CABG/valvular) or percutaneous valvular interventio
• Previously known specific myocardial disease (hypertrophic cardiomyopathy, non-compaction cardiomyopathy (LVNC), right ventricular arrhythmogenic cardiomyopathy (ARVC), cardiac amyloidosis, cardiac sarcoidosis, haemochromatosis)
• End-stage renal disease (eGFR <15 ml/min or dialysis treatment, previous kidney transplantation)
• Significant physical disability, mobility limitation, or dependence on another person for assistance (patient is not self-sufficient) limits participation in the study

Related Conditions & MeSH terms

• Heart Failure
• Heart Failure With Preserved Ejection Fraction

Locations

Country	Name	City	State
n/a

Sponsors (3)

Lead Sponsor	Collaborator
University of Helsinki	Aarne Koskelo Foundation, Finnish Foundation for Cardiovascular Research

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Functional status	6-minute walking test (walk distance in meters)	6 months
Other	Quality of life	QoL by Kansas City Carddiomyopathy Questionnaire (KCCQ 0-100 with higher values indicating better QoL)	6 months
Primary	All- cause mortality	Death from any cause	1 year
Secondary	Heart Failure Hospitalisation	Hopsitalisation for worsening heart failure	12 months
Secondary	All cause mortality	Death from any cause	5 years
Secondary	Cardiovascular mortality	Death from cardiovascular causes	1 year